<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37402856</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein-Barr virus and the gut-brain axis.</ArticleTitle><Pagination><StartPage>4968</StartPage><EndPage>4976</EndPage><MedlinePgn>4968-4976</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-023-02161-5</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in a serious public health burden worldwide. In addition to respiratory, heart, and gastrointestinal symptoms, patients infected with SARS-CoV-2 experience a number of persistent neurological and psychiatric symptoms, known as long COVID or "brain fog". Studies of autopsy samples from patients who died from COVID-19 detected SARS-CoV-2 in the brain. Furthermore, increasing evidence shows that Epstein-Barr virus (EBV) reactivation after SARS-CoV-2 infection might play a role in long COVID symptoms. Moreover, alterations in the microbiome after SARS-CoV-2 infection might contribute to acute and long COVID symptoms. In this article, the author reviews the detrimental effects of COVID-19 on the brain, and the biological mechanisms (e.g., EBV reactivation, and changes in the gut, nasal, oral, or lung microbiomes) underlying long COVID. In addition, the author discusses potential therapeutic approaches based on the gut-brain axis, including plant-based diet, probiotics and prebiotics, fecal microbiota transplantation, and vagus nerve stimulation, and sigma-1 receptor agonist fluvoxamine.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8892-0439</Identifier><AffiliationInfo><Affiliation>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, 260-8670, Japan. hashimoto@faculty.chiba-u.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21H00184</GrantID><Agency>MEXT | Japan Society for the Promotion of Science (JSPS)</Agency><Country/></Grant><Grant><GrantID>21H05612</GrantID><Agency>MEXT | Japan Society for the Promotion of Science (JSPS)</Agency><Country/></Grant><Grant><GrantID>21H02846</GrantID><Agency>MEXT | Japan Society for the Promotion of Science (JSPS)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087502" MajorTopicYN="Y">Brain-Gut Axis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="N">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="Y">Herpesvirus 4, Human</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>KH is the inventor of filed patent applications on &#x201c;The use of <i>R</i>-Ketamine in the treatment of psychiatric diseases&#x201d;, &#x201c;(<i>S</i>)-norketamine and salt thereof as pharmaceutical&#x201d;, &#x201c;<i>R</i>-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder&#x201d;, &#x201c;Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases&#x201d;, and &#x201c;<i>R</i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder&#x201d; by the Chiba University. KH has also received speakers&#x2019; honoraria, consultant fee, or research support from Abbott, Boehringer-Ingelheim, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>5</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>4</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37402856</ArticleId><ArticleId IdType="pmc">PMC11041741</ArticleId><ArticleId IdType="doi">10.1038/s41380-023-02161-5</ArticleId><ArticleId IdType="pii">10.1038/s41380-023-02161-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611&#x2013;27. doi: 10.1016/S2215-0366(20)30203-0..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30203-0.</ArticleId><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4:e2111417. doi: 10.1001/jamanetworkopen.2021.11417..</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417.</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendation. Nat Rev Microbiol. 2023;21:133&#x2013;46. doi: 10.1038/s41579-022-00846-2..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2.</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondratiuk AL, Pillay TD, Kon OM, Lalvani A. A conceptual framework to accelerate the clinical impact of evolving research into long COVID. Lancet Infect Dis. 2021;21:756&#x2013;7. doi: 10.1016/S1473-3099(21)00136-5..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00136-5.</ArticleId><ArticleId IdType="pmc">PMC8062085</ArticleId><ArticleId IdType="pubmed">33894903</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman EA, O'Kane CM, McAuley DF. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequalae, and management. Lancet. 2022;400:1157&#x2013;70. doi: 10.1016/S0140-6736(22)01439-8..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01439-8.</ArticleId><ArticleId IdType="pubmed">36070788</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators. Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;15. doi: 10.1001/jama.2022.18931..</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931.</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9.</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gennaro F, Belati A, Tulone O, Diella L, Fiore Bavaro D, Bonica R, et al. Incidence of long COVID-19 in people with previous SARS-Cov2 infection: a systematic review and meta-analysis of 120,970 patients. Intern Emerg Med. 2022:1&#x2013;9. 10.1007/s11739-022-03164-w.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9709360</ArticleId><ArticleId IdType="pubmed">36449260</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568..</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568.</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020.</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, et al. A systematic review and meta-analysis of long-term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28:423&#x2013;33. doi: 10.1038/s41380-022-01614-7..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01614-7.</ArticleId><ArticleId IdType="pmc">PMC9168643</ArticleId><ArticleId IdType="pubmed">35668159</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles VG, L&#xfc;tgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383:590&#x2013;2. doi: 10.1056/NEJMc2011400..</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2011400.</ArticleId><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, et al. Neuropathological features of covid-19. N Engl J Med 2020. 2020;383:989&#x2013;92. doi: 10.1056/NEJMc2019373..</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2019373.</ArticleId><ArticleId IdType="pmc">PMC7304421</ArticleId><ArticleId IdType="pubmed">32530583</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218:e20202135. doi: 10.1084/jem.20202135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202135</ArticleId><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;63. doi: 10.1038/s41586-022-05542-y..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y.</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18&#x2013;22. doi: 10.1016/j.bbi.2020.03.031..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.03.031.</ArticleId><ArticleId IdType="pmc">PMC7146689</ArticleId><ArticleId IdType="pubmed">32240762</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiatry. 2021;78:682&#x2013;3. doi: 10.1001/jamapsychiatry.2021.0500..</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2021.0500.</ArticleId><ArticleId IdType="pmc">PMC9894299</ArticleId><ArticleId IdType="pubmed">33769431</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson MA, Rhea EM, Knopp RC, Banks WA. Interactions of SARS-CoV-2 with the blood-brain barrier. Int J Mol Sci. 2021;22:2681. doi: 10.3390/ijms22052681..</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052681.</ArticleId><ArticleId IdType="pmc">PMC7961671</ArticleId><ArticleId IdType="pubmed">33800954</ArticleId></ArticleIdList></Reference><Reference><Citation>Normandin E, Valizadeh N, Rudmann EA, Uddin R, Dobbins ST, MacInnis BL, et al. Neuropathological features of SARS-CoV-2 delta and omicron variants. J Neuropathol Exp Neurol. 2023;82:283&#x2013;95. doi: 10.1093/jnen/nlad015..</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlad015.</ArticleId><ArticleId IdType="pmc">PMC10025880</ArticleId><ArticleId IdType="pubmed">36847705</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldfield PR, Hibberd J, Bridle BW. How does severe acute respiratory syndrome-coronavirus-2 affect the brain and its implications for the vaccines currently in use. Vaccines (Basel) 2021;10:1. doi: 10.3390/vaccines10010001..</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010001.</ArticleId><ArticleId IdType="pmc">PMC8780773</ArticleId><ArticleId IdType="pubmed">35062662</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovszki D, Walter FR, Vigh JP, Kocsis A, Valkai S, Deli MA, et al. Penetration of the SARS-CoV-2 spike protein across the blood-brain barrier, as revealed by a combination of a human cell culture model system and optical biosensing. Biomedicines. 2022;10:188. doi: 10.3390/biomedicines10010188..</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10010188.</ArticleId><ArticleId IdType="pmc">PMC8773803</ArticleId><ArticleId IdType="pubmed">35052867</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhea EM, Logsdon AF, Hansen KM, Williams LM, Reed MJ, Baumann KK, et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci. 2021;24:368&#x2013;78. doi: 10.1038/s41593-020-00771-8..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00771-8.</ArticleId><ArticleId IdType="pmc">PMC8793077</ArticleId><ArticleId IdType="pubmed">33328624</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhou L, Bao L, Liu J, Zhu H, Lv Q, et al. SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target. 2021;6:337. doi: 10.1038/s41392-021-00719-9..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00719-9.</ArticleId><ArticleId IdType="pmc">PMC8419672</ArticleId><ArticleId IdType="pubmed">34489403</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis A, Jain R, Frontera J, Placantonakis DG, Galetta S, Balcer L, et al. COVID-19 associated brain/spinal cord lesions and leptomeningeal enhancement: a meta-analysis of the relationship to CSF SARS-CoV-2. J Neuroimaging. 2021;31:826&#x2013;48. doi: 10.1111/jon.12880..</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jon.12880.</ArticleId><ArticleId IdType="pmc">PMC8242764</ArticleId><ArticleId IdType="pubmed">34105198</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697&#x2013;707. doi: 10.1038/s41586-022-04569-5..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5.</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollmann N, Beer AJ, Kirchhoff F. SARS-CoV-2 infection and the brain: direct evidence for brain changes in milder cases. Signal Transduct Target Ther. 2022;7:230. doi: 10.1038/s41392-022-01072-1..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01072-1.</ArticleId><ArticleId IdType="pmc">PMC9272648</ArticleId><ArticleId IdType="pubmed">35817774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer S, J&#xe4;ger HR. Brain changes after COVID-19 - how concerned should we be? Nat Rev Neurol. 2022;18:321&#x2013;2. doi: 10.1038/s41582-022-00661-6..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-022-00661-6.</ArticleId><ArticleId IdType="pmc">PMC9022737</ArticleId><ArticleId IdType="pubmed">35449462</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavda VP, Vora LK, Pandya AK, Patravale VB. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov Today. 2021;26:2619&#x2013;36. doi: 10.1016/j.drudis.2021.07.021..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2021.07.021.</ArticleId><ArticleId IdType="pmc">PMC8319039</ArticleId><ArticleId IdType="pubmed">34332100</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehervari Z. Intranasal vaccination. Nat Immunol. 2021;22:1071. doi: 10.1038/s41590-021-01016-x..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01016-x.</ArticleId><ArticleId IdType="pubmed">34429547</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan AO, Shrihari S, Gorman MJ, Ying B, Yuan D, Raju S, et al. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Cell Rep. 2021;36:109452. doi: 10.1016/j.celrep.2021.109452..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109452.</ArticleId><ArticleId IdType="pmc">PMC8270739</ArticleId><ArticleId IdType="pubmed">34289385</ArticleId></ArticleIdList></Reference><Reference><Citation>Alu A, Chen L, Lei H, Wei Y, Tian X, Wei X. Intranasal COVID-19 vaccines: from bench to bed. EBioMedicine. 2022;76:103841. doi: 10.1016/j.ebiom.2022.103841..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103841.</ArticleId><ArticleId IdType="pmc">PMC8785603</ArticleId><ArticleId IdType="pubmed">35085851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release. 2014;189:133&#x2013;40. doi: 10.1016/j.jconrel.2014.06.053..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2014.06.053.</ArticleId><ArticleId IdType="pubmed">24997277</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JI. Epstein&#x2013;Barr virus infection. N Engl J Med. 2000;343:481&#x2013;92. doi: 10.1056/NEJM200008173430707..</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200008173430707.</ArticleId><ArticleId IdType="pubmed">10944566</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiee A, Aghajanian S, Athar MMT, Gargari OK. Epstein&#x2013;Barr virus and COVID-19. J Med Virol. 2022;94:4040&#x2013;2. doi: 10.1002/imv.27823..</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/imv.27823.</ArticleId><ArticleId IdType="pmc">PMC9348397</ArticleId><ArticleId IdType="pubmed">35505635</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Epstein&#x2013;Barr virus and infectious mononucleosis. 2020. https://www.cdc.gov.epstein-barr/.</Citation></Reference><Reference><Citation>Aloisi F, Giovannoni G, Salvetti M. Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy. Lancet Neurol. 2023;22:338&#x2013;49. doi: 10.1016/S1474-4422(22)00471-9..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(22)00471-9.</ArticleId><ArticleId IdType="pubmed">36764322</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, M&#xfc;nz C, Cohen JI, Ascherio A. Epstein&#x2013;Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat Rev Neurol. 2023;19:160&#x2013;71. doi: 10.1038/s41582-023-00775-5..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-023-00775-5.</ArticleId><ArticleId IdType="pubmed">36759741</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Song J, Liu H, Zheng H, Chen C. Positive Epstein&#x2013;Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep. 2021;11:10902. doi: 10.1038/s41598-021-90351-y..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-90351-y.</ArticleId><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10:763. doi: 10.3390/pathogens10060763..</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763.</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;95.e20. doi: 10.1016/j.cell.2022.01.014..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014.</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv. 2022. 10.1101/2022.08.09.22278592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, Ryder DM, Buck AM, Beck-Engeser G, et al. Impact of pre-existing chronic viral infection and reactivation on the development of long COVID. J Clin Invest. 2023;133:e163669. doi: 10.1172/JCI163669..</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669.</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganelli R. Resurrecting Epstein&#x2013;Barr virus. Pathogens. 2022;11:772. doi: 10.3390/pathogens11070772..</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11070772.</ArticleId><ArticleId IdType="pmc">PMC9318925</ArticleId><ArticleId IdType="pubmed">35890017</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC. X-box-binding protein 1 activates lytic Epstein&#x2013;Barr virus gene expression in combination with protein kinase D. J Virol. 2007;81:7363&#x2013;70. doi: 10.1128/JVI.00154-07..</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00154-07.</ArticleId><ArticleId IdType="pmc">PMC1933364</ArticleId><ArticleId IdType="pubmed">17494074</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell. 2007;131:596&#x2013;610. doi: 10.1016/j.cell.2007.08.036..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.08.036.</ArticleId><ArticleId IdType="pubmed">17981125</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T. The sigma-1 receptor in cellular stress signaling. Front Neurosci. 2019;13:733. doi: 10.3389/fnins.2019.00733..</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00733.</ArticleId><ArticleId IdType="pmc">PMC6646578</ArticleId><ArticleId IdType="pubmed">31379486</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T. Sigma-1 receptor: the novel intracellular target of neuropsychotherapeutic drugs. J Pharmacol Sci. 2015;127:2&#x2013;5. doi: 10.1016/j.jphs.2014.07.001..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2014.07.001.</ArticleId><ArticleId IdType="pubmed">25704011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. 2021;271:249&#x2013;58. doi: 10.1007/s00406-020-01231-x..</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-020-01231-x.</ArticleId><ArticleId IdType="pmc">PMC7785036</ArticleId><ArticleId IdType="pubmed">33403480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci. 2022;272:161&#x2013;3. doi: 10.1007/s00406-021-01326-z..</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-021-01326-z.</ArticleId><ArticleId IdType="pmc">PMC8412866</ArticleId><ArticleId IdType="pubmed">34476589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry. 2022;27:1898&#x2013;907. doi: 10.1038/s41380-021-01432-3..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01432-3.</ArticleId><ArticleId IdType="pmc">PMC8739627</ArticleId><ArticleId IdType="pubmed">34997196</ArticleId></ArticleIdList></Reference><Reference><Citation>Khani E, Entezari-Maleki T. Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists. Mol Psychiatry. 2022;27:3562. doi: 10.1038/s41380-022-01545-3..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01545-3.</ArticleId><ArticleId IdType="pmc">PMC8985056</ArticleId><ArticleId IdType="pubmed">35388182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Suzuki T, Hashimoto K. Comments to &#x201c;Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists&#x201d; by Khani and Entezari-Maleki. Mol Psychiatry. 2022;27:3563&#x2013;4. doi: 10.1038/s41380-022-01546-2..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01546-2.</ArticleId><ArticleId IdType="pmc">PMC8985059</ArticleId><ArticleId IdType="pubmed">35388183</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Overview of the potential use of fluvoxamine for COVID-19 and long COVID. Discov Ment Health. 2023;3:9. doi: 10.1007/s44192-023-00036-3..</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44192-023-00036-3.</ArticleId><ArticleId IdType="pmc">PMC10029802</ArticleId><ArticleId IdType="pubmed">36968793</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidky H, Sahner DK, Girvin AT, Hotaling N, Michael SG, Kurilla MG, et al. Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. medRxiv. 2022. 10.1101/2022.11.09.22282142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10839808</ArticleId><ArticleId IdType="pubmed">38318198</ArticleId></ArticleIdList></Reference><Reference><Citation>Farahani RH, Ajam A, Naeini AR. Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. 2023;23:197. doi: 10.1186/s12879-023-08172-5..</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08172-5.</ArticleId><ArticleId IdType="pmc">PMC10064948</ArticleId><ArticleId IdType="pubmed">37003990</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedberg DE, Chang L. Gastrointestinal symptoms in COVID-19: the long and the short of it. Curr Opin Gastroenterol. 2022;38:555&#x2013;61. doi: 10.1097/MOG.0000000000000876..</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOG.0000000000000876.</ArticleId><ArticleId IdType="pubmed">36165028</ArticleId></ArticleIdList></Reference><Reference><Citation>Meringer H, Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. Nat Rev Gastroenterol Hepatol. 2022;19:345&#x2013;6. doi: 10.1038/s41575-022-00611-z..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-022-00611-z.</ArticleId><ArticleId IdType="pmc">PMC8981882</ArticleId><ArticleId IdType="pubmed">35383321</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Lau RI, Liu Q, Su Q, Chan FKL, Ng SC. Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications. Nat Rev Gastroenterol Hepatol. 2023;20:323&#x2013;37. doi: 10.1038/s41575-022-00698-4..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-022-00698-4.</ArticleId><ArticleId IdType="pmc">PMC9589856</ArticleId><ArticleId IdType="pubmed">36271144</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T, Liu Q, Zhang F, Lui GC, Tso EY, Yeoh YK, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021;70:276&#x2013;84. doi: 10.1136/gutjnl-2020-322294..</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322294.</ArticleId><ArticleId IdType="pmc">PMC7385744</ArticleId><ArticleId IdType="pubmed">32690600</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (NY) 2022;3:371&#x2013;87.e9. doi: 10.1016/j.medj.2022.04.001..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001.</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilpert K, Mikut R. Is there a connection between gut microbiome dysbiosis occurring in COVID-19 patients and post-COVID-19 symptoms? Front Microbiol. 2021;12:732838. doi: 10.3389/fmicb.2021.732838..</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.732838.</ArticleId><ArticleId IdType="pmc">PMC8485028</ArticleId><ArticleId IdType="pubmed">34603261</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the mystery surrounding post-acute sequalae of COVID-19. Front Immunol. 2021;12:686029. doi: 10.3389/fimmu.2021.686029..</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686029.</ArticleId><ArticleId IdType="pmc">PMC8278217</ArticleId><ArticleId IdType="pubmed">34276671</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Wan Y, Zuo T, Yeoh YK, Liu Q, Zhang L, et al. Prolonged impairment of short-chain fatty acid and L-isoleucine biosynthesis in gut microbiome in patients with COVID-19. Gastroenterology. 2022;162:548&#x2013;61.e4. doi: 10.1053/j.gastro.2021.10.013..</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.10.013.</ArticleId><ArticleId IdType="pmc">PMC8529231</ArticleId><ArticleId IdType="pubmed">34687739</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T, Wu X, Wen W, Lan P. Gut microbiome alterations in COVID-19. Genomics Proteomics Bioinformatics. 2021;19:679&#x2013;88. doi: 10.1016/j.gpb.2021.09.004..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gpb.2021.09.004.</ArticleId><ArticleId IdType="pmc">PMC8478109</ArticleId><ArticleId IdType="pubmed">34560321</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70:698&#x2013;706. doi: 10.1136/gutjnl-2020-323020..</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323020.</ArticleId><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng X, Zhang Y, Li Y, Wu Q, Wu J, Park SK, et al. Meta-analysis of 16S rRNA microbial data identified alterations of the gut microbiota in COVID-19 patients during the acute and recovery phases. BMC Microbiol. 2022;222:274. doi: 10.1186/s12866-022-02686-9..</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-022-02686-9.</ArticleId><ArticleId IdType="pmc">PMC9662111</ArticleId><ArticleId IdType="pubmed">36376804</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv L, Jiang H, Chen Y, Gu S, Xia J, Zhang H, et al. The faecal metabolome in COVID-19 patients is altered and associated with clinical features and gut microbes. Anal Chim Acta. 2021;1152:338267. doi: 10.1016/j.aca.2021.338267..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aca.2021.338267.</ArticleId><ArticleId IdType="pmc">PMC7847702</ArticleId><ArticleId IdType="pubmed">33648648</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng SSS, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71:544&#x2013;52. doi: 10.1136/gutjnl-2021-325989..</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989.</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Su Q, Zhang F, Tun HM, Mak JWY, Lui GC, et al. Multi-kingdom gut microbiota analyses define COVID-19 severity and post-acute COVID-19 syndrome. Nat Commun. 2022;13:6806. doi: 10.1038/s41467-022-34535-8..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34535-8.</ArticleId><ArticleId IdType="pmc">PMC9648868</ArticleId><ArticleId IdType="pubmed">36357381</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron LB, Peluso MJ, Ding J, Kenny G, Zilberstein NF, Koshy J, et al. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-&#x3ba;B signaling. JCI Insight. 2022;7:e160989. doi: 10.1172/jci.insight.160989..</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.160989.</ArticleId><ArticleId IdType="pmc">PMC9675436</ArticleId><ArticleId IdType="pubmed">36134654</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun. 2020;87:59&#x2013;73. doi: 10.1016/j.bbi.2020.04.046..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.04.046.</ArticleId><ArticleId IdType="pmc">PMC7175848</ArticleId><ArticleId IdType="pubmed">32334062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Jing H, Wang C, Wang Y, Zuo N, Jiang T, et al. Intestinal damage in COVID-19: SARS-CoV-2 infection and intestinal thrombosis. Front Microbiol. 2022;13:860931. doi: 10.3389/fmicb.2022.860931..</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.860931.</ArticleId><ArticleId IdType="pmc">PMC8981312</ArticleId><ArticleId IdType="pubmed">35391725</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimar&#xe3;es Sousa S, Kleiton de Sousa A, Maria Carvalho Pereira C, Sofia Miranda Loiola Ara&#xfa;jo A, de Aguiar Magalh&#xe3;es D, Vieira de Brito T, et al. SARS-CoV-2 infection causes intestinal cell damage: Role of interferon&#x2019;s imbalance. Cytokine. 2022;152:155826. doi: 10.1016/j.cyto.2022.155826..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2022.155826.</ArticleId><ArticleId IdType="pmc">PMC8828414</ArticleId><ArticleId IdType="pubmed">35158258</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardelli C, Scaglione GL, Testa D, Setaro M, Russo F, Di Domenico C, et al. Nasal microbiome in COVID-19: a potential role of Corynebacterium in anosmia. Curr Microbiol. 2022;80:53. doi: 10.1007/s00284-022-03106-x..</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-022-03106-x.</ArticleId><ArticleId IdType="pmc">PMC9802018</ArticleId><ArticleId IdType="pubmed">36583787</ArticleId></ArticleIdList></Reference><Reference><Citation>Haran JP, Bradley E, Zeamer AL, Cincotta L, Salive MC, Dutta P, et al. Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID. JCI Insight. 2021;6:e152346. doi: 10.1172/jci.insight.152346..</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.152346.</ArticleId><ArticleId IdType="pmc">PMC8564890</ArticleId><ArticleId IdType="pubmed">34403368</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteside SA, McGinniss JE, Collman RG. The lung microbiome: progress and promise. J Clin Invest. 2021;131:e150473. doi: 10.1172/JCI150473..</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI150473.</ArticleId><ArticleId IdType="pmc">PMC8321564</ArticleId><ArticleId IdType="pubmed">34338230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Eguchi A, Wei Y, Shinno-Hashimoto H, Fujita Y, Ishima T, et al. Antibiotic-induced microbiome depletion improves LPS-induced acute lung injury via gut-lung axis. Life Sci. 2022;307:120885. doi: 10.1016/j.lfs.2022.120885..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2022.120885.</ArticleId><ArticleId IdType="pubmed">35981631</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosang L, Canals RC, van der Flier FJ, Hollensteiner J, Daniel R, Fl&#xfc;gel A, et al. The lung microbiome regulates brain autoimmunity. Nature. 2022;603:138&#x2013;44. doi: 10.1038/s41586-022-04427-4..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04427-4.</ArticleId><ArticleId IdType="pubmed">35197636</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng SC, Peng Y, Zhang L, Mok CK, Zhao S, Li A, et al. Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. Gut. 2022;71:1106&#x2013;16. doi: 10.1136/gutjnl-2021-326563..</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-326563.</ArticleId><ArticleId IdType="pmc">PMC8844967</ArticleId><ArticleId IdType="pubmed">35140064</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang B, Tang L, He W, Jiang X, Hu C, Li Y, et al. Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine. Cell Rep Med. 2022;3:100752. doi: 10.1016/j.xcrm.2022.100752..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100752.</ArticleId><ArticleId IdType="pmc">PMC9589008</ArticleId><ArticleId IdType="pubmed">36228621</ArticleId></ArticleIdList></Reference><Reference><Citation>Merino J, Joshi AD, Nguyen LH, Leeming ER, Mazidi M, Drew DA, et al. Diet quality and risk and severity of COVID-19: a prospective cohort study. Gut. 2021;70:2096&#x2013;104. doi: 10.1136/gutjnl-2021-325353..</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325353.</ArticleId><ArticleId IdType="pmc">PMC8500931</ArticleId><ArticleId IdType="pubmed">34489306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou YC, Su WL, Chao YC. COVID-19 illness severity in the elderly in relation to vegetarian and non-vegetarian diets: a single center experience. Front Nutr. 2022;9:837458. doi: 10.3389/fnut.2022.837458..</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.837458.</ArticleId><ArticleId IdType="pmc">PMC9101048</ArticleId><ArticleId IdType="pubmed">35571931</ArticleId></ArticleIdList></Reference><Reference><Citation>Guti&#xe9;rrez-Castrell&#xf3;n P, Gandara-Mart&#xed; T, Abreu Y, Abreu AT, Nieto-Rufino CD, L&#xf3;pez-Ordu&#xf1;a E, et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022;14:2018899. doi: 10.1080/19490976.2021.2018899..</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2021.2018899.</ArticleId><ArticleId IdType="pmc">PMC8757475</ArticleId><ArticleId IdType="pubmed">35014600</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegazy M, Ahmed Ashoush O, Tharwat Hegazy M, Wahba M, Lithy RM, Abdel-Hamid HM, et al. Beyond probiotic legend: ESSAP gut microbiota health score to delineate SARS-COV-2 infection severity. Br J Nutr. 2022;127:1180&#x2013;9. doi: 10.1017/S0007114521001926..</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114521001926.</ArticleId><ArticleId IdType="pmc">PMC8410748</ArticleId><ArticleId IdType="pubmed">34096487</ArticleId></ArticleIdList></Reference><Reference><Citation>Neris Almeida Viana S, do Reis Santos Pereira T, de Carvalho Alves J, Tianeze de Castro C, Santana C da Silva L, et al. Benefits of probiotic use on COVID-19: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022:1&#x2013;13. 10.1080/10408398.2022.2128713.</Citation><ArticleIdList><ArticleId IdType="pubmed">36178362</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019;16:461&#x2013;78. doi: 10.1038/s41575-019-0157-3..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0157-3.</ArticleId><ArticleId IdType="pubmed">31123355</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva YP, Bernardi A, Frozza LR. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol. 2020;11:25. doi: 10.3389/fendo.2020.00025..</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.00025.</ArticleId><ArticleId IdType="pmc">PMC7005631</ArticleId><ArticleId IdType="pubmed">32082260</ArticleId></ArticleIdList></Reference><Reference><Citation>Gang J, Wang H, Xue X, Zhang S. Microbiota and COVID-19: Long-term and complex influencing factors. Front Microbiol. 2022;13:963488. doi: 10.3389/fmicb.2022.963488..</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.963488.</ArticleId><ArticleId IdType="pmc">PMC9417543</ArticleId><ArticleId IdType="pubmed">36033885</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Ye S, Zhu X, He X, Wang S, Li Y, et al. Gastrointestinal disturbance and effect of fecal microbiota transplantation in discharged COVID-19 patients. J Med Case Rep. 2021;15:60. doi: 10.1186/s13256-020-02583-7..</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-020-02583-7.</ArticleId><ArticleId IdType="pmc">PMC7868905</ArticleId><ArticleId IdType="pubmed">33557941</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilinski J, Winter K, Jasinski M, Szczes A, Bilinska N, Mullish BH, et al. Rapid resolution of COVID-19 after faecal microbiota transplantation. Gut. 2022;71:230&#x2013;2. doi: 10.1136/gutjnl-2021-325010..</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325010.</ArticleId><ArticleId IdType="pubmed">34230217</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xfc;lling C, Dinan TG, Cryan JF. Gut microbe to brain signaling: what happens in vagus. Neuron. 2019;101:998&#x2013;1002. doi: 10.1016/j.neuron.2019.02.008..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.008.</ArticleId><ArticleId IdType="pubmed">30897366</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, Wei Y, Hashimoto K. Brain-gut-microbiota axis in depression: a historical overview and future directions. Brain Res Bull. 2022;182:44&#x2013;56. doi: 10.1016/j.brainresbull.2022.02.004..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2022.02.004.</ArticleId><ArticleId IdType="pubmed">35151796</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, Wang T, Liao L, Fan X, Chang L, Hashimoto K. Brain-spleen axis in health and diseases: a review and future perspective. Brain Res Bull. 2022;182:130&#x2013;40. doi: 10.1016/j.brainresbull.2022.02.008..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2022.02.008.</ArticleId><ArticleId IdType="pubmed">35157987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Neuroinflammation through the vagus nerve-dependent gut&#x2013;microbiota&#x2013;brain axis in treatment-resistant depression. Prog Brain Res. in press. 10.1016/bs.pbr.2023.01.003.</Citation><ArticleIdList><ArticleId IdType="pubmed">37414494</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Ma L, Chang L, Pu Y, Qu Y, Hashimoto K. A key role of the subdiaphragmatic vagus nerve in the depression-like phenotype and abnormal composition of gut microbiota in mice after lipopolysaccharide administration. Transl Psychiatry. 2020;10:186. doi: 10.1038/s41398-020-00878-3..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-00878-3.</ArticleId><ArticleId IdType="pmc">PMC7283282</ArticleId><ArticleId IdType="pubmed">32518376</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Ishima T, Zhang J, Qu Y, Chang L, Pu Y, et al. Ingestion of Lactobacillus intestinalis and Lactobacillus reuteri causes depression- and anhedonia-like phenotypes in antibiotic-treated mice via the vagus nerve. J Neuroinflammation. 2020;17:241. doi: 10.1186/s12974-020-01916-z..</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01916-z.</ArticleId><ArticleId IdType="pmc">PMC7429467</ArticleId><ArticleId IdType="pubmed">32799901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu Y, Tan Y, Qu Y, Chang L, Wang S, Wei Y, et al. A role of the subdiaphragmatic vagus nerve in depression-like phenotypes in mice after fecal microbiota transplantation from Chrna7 knock&#x2013;out mice with depression-like phenotypes. Brain Behav Immun. 2021;94:318&#x2013;26. doi: 10.1016/j.bbi.2020.12.032..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.12.032.</ArticleId><ArticleId IdType="pubmed">33422641</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Eguchi A, Wan X, Chang L, Wang X, Qu Y, et al. A role of gut-microbiota-brain axis via subdiaphragmatic vagus nerve in depression-like phenotypes in Chrna7 knock-out mice. Prog Neuropsychopharmacol Biol Psychiatry. 2023;120:110652. doi: 10.1016/j.pnpbp.2022.110652..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2022.110652.</ArticleId><ArticleId IdType="pubmed">36191806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Eguchi A, Yang Y, Chang L, Wan X, Shan J, et al. Key role of the gut-microbiota-brain axis via the subdiaphragmatic vagus nerve in demyelination of the cuprizone-treated mouse brain. Neurobiol Dis. 2023;176:105951. doi: 10.1016/j.nbd.2022.105951..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2022.105951.</ArticleId><ArticleId IdType="pubmed">36493975</ArticleId></ArticleIdList></Reference><Reference><Citation>Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458&#x2013;62. doi: 10.1038/35013070..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35013070.</ArticleId><ArticleId IdType="pubmed">10839541</ArticleId></ArticleIdList></Reference><Reference><Citation>Azabou E, Bao G, Bounab R, Heming N, Annane D. Vagus nerve stimulation: a potential adjunct therapy for COVID-19. Front Med (Lausanne) 2021;8:625836. doi: 10.3389/fmed.2021.625836..</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.625836.</ArticleId><ArticleId IdType="pmc">PMC8137825</ArticleId><ArticleId IdType="pubmed">34026778</ArticleId></ArticleIdList></Reference><Reference><Citation>Corr&#xea;a FI, Souza PHL, Uehara L, Ritti-Dias RM, Oliveira da Silva G, Segheto W, et al. Transcutaneous auricular vagus nerve stimulation improves inflammation but does not interfere with cardiac modulation and clinical symptoms of individuals with COVID-19: a randomized clinical trial. Life (Basel) 2022;12:1644. doi: 10.3390/life12101644..</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12101644.</ArticleId><ArticleId IdType="pmc">PMC9604701</ArticleId><ArticleId IdType="pubmed">36295080</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>